제약 및 바이오테크놀러지 분야 옵션 및 평가 계약(2019-2026년)

Understand how pharmaceutical and biotechnology companies use option and evaluation agreements to secure future rights, assess opportunities and manage early-stage partnering risk.

Option and Evaluation Deals in Pharmaceuticals and Biotechnology provides comprehensive intelligence on 1,419 option and evaluation deals across the global life sciences industry.

Option-based partnerships allow companies to evaluate an asset, technology or development opportunity before committing to a broader licensing, development or acquisition transaction. They can provide the prospective partner with defined future rights while enabling the originating company to access funding, expertise or validation during the evaluation period.

The report examines how these transactions are being used across pharmaceutical and biotechnology partnering, which companies are most active, where dealmaking is concentrated and what can be learned from disclosed financial terms and publicly available contract documents.

Rather than simply identifying transactions, the report helps users understand what is being evaluated, how option rights are structured, what triggers future partnering rights, how financial consideration is staged and how comparable agreements have been negotiated in practice.

It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, legal and transaction teams evaluating or negotiating option-based partnerships.

Understand the option and evaluation deal landscape

The report analyzes option and evaluation dealmaking from 2019 to 2026, including:

• Trends in option and evaluation dealmaking by year
• Phase of development at the time of partnering
• Industry sector
• Therapy area
• Technology type
• Most active option and evaluation dealmakers
• Leading deals by disclosed value
• Strategic reasons for entering option-based partnerships
• How option and evaluation strategies are evolving
• This provides insight into where companies are using option structures, which technologies and therapeutic areas are attracting activity and which organizations are most actively pursuing this form of staged partnering.
• Understand how option and evaluation agreements are structured
• Option and evaluation agreements can take many forms, but typically provide one party with defined rights to evaluate an opportunity and potentially enter a subsequent transaction.

The report provides intelligence to help users examine areas including:

• Scope of evaluation rights
• Option rights and exercise mechanisms
• Evaluation periods
• Exclusivity during evaluation
• Research and development responsibilities
• Intellectual property ownership and access
• Information and data rights
• Option exercise triggers
• Future licensing or development rights
• Development and commercialization responsibilities
• Option fees and other payments
• Milestones and other financial terms where disclosed
• Term and termination provisions
• These real-world examples provide useful reference points when deciding how much flexibility, exclusivity and future commitment should be incorporated into an option-based partnership.
• Benchmark option and evaluation deal financials
• The report provides access to disclosed financial information associated with individual option and evaluation agreements.

Depending on the transaction, users can investigate elements including:

• Evaluation payments
• Option fees
• Upfront payments
• Research funding
• Option exercise payments
• Development and regulatory milestones
• Commercial milestones
• Royalty arrangements
• Equity investment
• Other financial commitments where disclosed
• Leading transactions are also ranked by disclosed deal value, enabling users to identify significant precedent deals and investigate their underlying structures.
• This provides evidence from real-world transactions to support deal preparation, internal benchmarking and negotiation.
• Identify active option and evaluation dealmakers
• The report profiles the Top 25 most active option and evaluation dealmakers, helping users identify companies repeatedly using staged partnering structures to access external innovation.

Transaction histories can help users understand:

• Which companies regularly enter option-based agreements
• Technologies and therapeutic areas attracting their interest
• Development stages at which companies are prepared to engage
• Potential partners for assets or technologies
• Previous transactions providing relevant precedents
• This makes the report particularly useful for business development, search and evaluation and competitive intelligence teams seeking organizations with a demonstrated appetite for emerging opportunities.
• Learn from real-world option and evaluation contracts
• Where publicly available, the report provides access to underlying option and evaluation contract documents.

These agreements can reveal significantly more than headline announcements, allowing users to examine how companies have documented provisions relating to:

• Evaluation rights and periods
• Option grant and exercise
• Exclusivity
• Intellectual property
• Development responsibilities
• Information and diligence obligations
• Option fees and financial consideration
• Future licensing rights
• Milestones and royalties
• Termination and expiry
• For teams preparing an option-based transaction, access to real agreement language provides valuable insight into how comparable provisions have been structured in practice.
• Comprehensive option and evaluation deal directory
• The report includes a comprehensive directory of 1,419 option and evaluation deals, enabling users to identify transactions relevant to their own assets, technologies and partnering objectives.

Deals can be reviewed by:

• Company
• Therapy area
• Technology type
• Contract availability
• Individual transactions are linked to their underlying deal records, providing a route to further deal information and associated contract documentation where available.
• Who should use this report?
• Business Development and Licensing teams
• Identify comparable option agreements, prospective partners and relevant structures when preparing staged partnering strategies.
• Search and Evaluation teams
• Understand which companies are using options to secure access to emerging assets and technologies and investigate their previous partnering activity.
• Biotechnology Companies Seeking Partners
• Identify organizations prepared to engage with technologies and assets before a full licensing commitment is appropriate.
• Corporate and R&D Strategy teams
• Understand how companies use staged investment and evaluation rights to access external innovation while managing development risk.
• Legal and Transaction teams
• Review real-world agreement structures and publicly available contract language covering option rights, evaluation periods, exclusivity and future licensing provisions.
• Competitive Intelligence teams
• Track option activity to understand where companies are securing early access to technologies, assets and emerging areas of innovation.
• Turn market-wide intelligence into company-specific insight
• For qualifying customers, Current Partnering can also provide a Customized Executive Partnering Briefing alongside the report.
• The briefing applies the underlying option and evaluation deal intelligence to the customer's own assets, technologies or partnering objectives.
• Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, option structures, financial benchmarks, contract insights and other intelligence selected specifically for the client's situation.
• Request a sample or contact Current Partnering to discuss the report and whether a customized analysis can be provided for your organization.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in option and evaluation dealmaking

• 2.1. Introduction
• 2.2. Definition of option and evaluation deal
• 2.3. Trends in option and evaluation deals
  • 2.3.1. Option and evaluation dealmaking by year
  • 2.3.2. Option and evaluation dealmaking by phase of development
  • 2.3.3. Option and evaluation dealmaking by industry sector
  • 2.3.4. Option and evaluation dealmaking by therapy area
  • 2.3.5. Option and evaluation dealmaking by technology type
  • 2.3.6. Option and evaluation dealmaking by most active company
• 2.4. Reasons for entering into option and evaluation partnering deals
• 2.5. The future of option and evaluation deals

Chapter 3 - Overview of option and evaluation deal structure

• 3.1. Introduction
• 3.2. Option and evaluation agreement structure

Chapter 4 - Leading option and evaluation deals

• 4.1. Introduction
• 4.2. Top option and evaluation deals by value

Chapter 5 - Top 25 most active option and evaluation dealmakers

• 5.1. Introduction
• 5.2. Top 25 most active option and evaluation dealmakers

Chapter 6 - option and evaluation deals including contracts directory

• 6.1. Introduction
• 6.2. Option and evaluation deals with contracts
• Deal directory
• Deal directory - option and evaluation dealmaking by companies A-Z
• Deal directory - option and evaluation dealmaking by therapy area
• Deal directory - option and evaluation dealmaking by technology type
• About Biopharma Research
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Definition of option and evaluation
• Figure 2: Trends in option and evaluation deal announcements
• Figure 3: Option and evaluation deals signed at each phase of development
• Figure 4: Option and evaluation deals by industry sector
• Figure 5: Option and evaluation deals by therapy area
• Figure 6: Option and evaluation deals by technology type
• Figure 7: Top 25 most active option and evaluation dealmakers
• Figure 8: Top option and evaluation deals by value
• Figure 9: Most active option and evaluation dealmakers